CITIUS ONCOLOGY, INC.(CTOR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

CITIUS ONCOLOGY, INC. (CTOR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CTOR is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), CITIUS ONCOLOGY, INC. reports quarterly revenue of $1.5M, net income of $-8.9M. Top institutional holders of CTOR by reported 13-F value include ARMISTICE CAPITAL, BANK OF AMERICA, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CTOR trades on the Nasdaq exchange and files with the SEC under CIK 1851484. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CITIUS ONCOLOGY, INC. directly from SEC EDGAR.